Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cinrebafusp alfa combinations in HER2-positive and HER2-low gastric/GEJ adenocarcinoma
2020-002512-49Phase 2Terminated
- Sponsor
- Pieris Pharmaceuticals
- Start
- Feb 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of cinrebafusp alfa in HER2-positive gastric adenocarcinoma, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Pieris Pharmaceuticals. Primary endpoint: Objective response rate. Started Feb 2022; status: terminated.
02
Drugs
cinrebafusp alfa
03
Conditions
HER2-positive gastric adenocarcinomagastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2020-002512-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002512-49.